middle.news

CSL Delivers Steady Growth, Reaffirms FY25 Earnings Guidance

8:11am on Tuesday 11th of February, 2025 AEDT Pharmaceuticals
Read Story

CSL Delivers Steady Growth, Reaffirms FY25 Earnings Guidance

8:11am on Tuesday 11th of February, 2025 AEDT
Key Points
  • 5% revenue growth to US$8.47 billion at constant currency
  • 7% increase in net profit after tax (NPAT) to US$2.04 billion
  • Strong performance in CSL Behring and Vifor segments
  • Seqirus segment impacted by low immunisation rates and competitive pressures
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about CSL (ASX:CSL)
OPEN ARTICLE